Table 4.
Association between CD9 expression and clinicopathological characteristics in cancer patients
| Characteristic | Number of studies | Number of patients | Pooled OR (95% CI) | p value | Heterogeneity | ||
|---|---|---|---|---|---|---|---|
| I2 (%) | p value | Model | |||||
| Age (old vs young) | 10 | 2500 | 1.04 (0.88–1.22) | 0.670 | 23.0 | 0.232 | Fixed |
| Sex (male vs female) | 9 | 1119 | 0.76 (0.59–0.99) | 0.044 | 0.0 | 0.815 | Fixed |
| Tumor size (large vs small) | 3 | 1570 | 0.83 (0.44–1.55) | 0.554 | 68.5 | 0.042 | Random |
| Tumor grade (high vs low) | 6 | 2340 | 0.50 (0.16–1.60) | 0.244 | 94.9 | < 0.001 | Random |
| Tumor stage (high vs low) | 8 | 2524 | 0.56 (0.27–1.16) | 0.120 | 89.5 | < 0.001 | Random |
| Lymph node metastasis (present vs absent) | 8 | 2312 | 0.68 (0.41–1.13) | 0.137 | 83.0 | < 0.001 | Random |
| Overall stage (high vs low) | 7 | 930 | 0.45 (0.29–0.72) | 0.001 | 57.6 | 0.028 | Random |
CI confidence interval, OR odds ratio